GlobeNewswire (Mon, 7:30AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,349 people get ZGNX articles and Market Currents by email alert.
Get email alerts on ZGNX »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 3, 2013)
-
-
GlobeNewswire (May 2, 2013)
-
-
-
-
GlobeNewswire (Mar 27, 2013)
-
GlobeNewswire (Mar 15, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
-
GlobeNewswire (Feb 26, 2013)
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
FDA Advisory Meeting Leaves Zogenix Stock In TattersBrian L. Wilson • Fri, Dec 14, 2012 -
-
-
-
-
-
-
-
-
Zogenix's CEO Discusses Q3 2012 Results - Earnings Call TranscriptFri, Nov 9, 2012
-
Zogenix's CEO Discusses Q2 2012 Results - Earnings Call TranscriptWed, Aug 8, 2012
-
GlobeNewswire (Mon, 7:30AM)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 3, 2013)
-
GlobeNewswire (May 2, 2013)
-
GlobeNewswire (Mar 27, 2013)
-
GlobeNewswire (Mar 15, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
GlobeNewswire (Feb 26, 2013)
-
GlobeNewswire (Jan 7, 2013)
-
GlobeNewswire (Jan 3, 2013)
-
at MarketWatch.com (Jan 2, 2013)
-
at MarketWatch.com (Dec 10, 2012)
-
GlobeNewswire (Dec 7, 2012)
-
GlobeNewswire (Dec 7, 2012)
-
GlobeNewswire (Nov 26, 2012)
-
GlobeNewswire (Nov 15, 2012)
-
GlobeNewswire (Nov 13, 2012)
-
GlobeNewswire (Nov 8, 2012)
-
Zogenix Announces FDA Advisory Committee Review of Zohydro(TM) ER for the Management of Chronic PainGlobeNewswire (Nov 8, 2012)
-
GlobeNewswire (Oct 25, 2012)
ZGNX vs. ETF Alternatives
Company Description
Currently, there's no company description for ZGNX.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 10, 3:36 PM Shares of Endo Health (ENDP -3.6%) trade lower following a brief halt after the FDA denies its petition to block generic versions of its Opana ER. ZGNX +2.1%, IPXL +8.4%. Comment! [Healthcare, On the Move]
- Thursday, May 9, 7:50 PM More on Zogenix (ZGNX): Q1 misses on all counts. Net product revenues declined Y/Y, driven by the increase to the return reserve and the resetting of health insurance co-pays and co-insurance at the beginning of the year, which slowed patient volumes to a greater degree than in previous years. Product gross margin was 40%, compared to 49% in Q112, due to higher cost per unit and a decrease in the net selling price. Shares -2.4% AH. Comment! [Healthcare, Earnings, On the Move]
- Thursday, May 9, 4:11 PM Zogenix (ZGNX): Q1 EPS loss of -$0.21 misses by $0.07. Revenue of $7M (-24% Y/Y) misses by $2.28M. (PR). Conference Call at 4:30 ET: (Webcast). Comment! [Breaking News, Healthcare, Earnings]
- Thursday, May 9, 12:10 AM Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX Comment! [Earnings]
- Wednesday, May 8, 5:35 PM Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX Comment! [Earnings]
-
Wednesday, April 17, 9:12 AM
Premarket gainers: VRML +29%. ACUR +26%. OCZ +18%. CUR +9%. ALKS +9%. ABMD +9%. ASML +6%.
Losers: EOPN -29%. INWK -25%. CXW -15%. MHR -12%. ZGNX -11%. TXT -9%. CRUS -7%. VRNG -6%. 1 Comment [On the Move] - Wednesday, March 27, 2:14 PM Zogenix (ZGNX -0.8%) and Battelle, the world's largest independent research and development organization, say they've extended a co-marketing partnership for the DosePro needle-free drug delivery system through March, 2014. The partnership is focused on advancing the out-licensing opportunities for the system, with a focus on co-marketing the technology to potential biopharmaceutical and government clients. Comment! [Healthcare, On the Move]
- Friday, March 15, 12:20 PM Drug developer Zogenix (ZGNX +4.3%) moves up today after posting a narrower-than-expected Q4 loss. Total sales came in at $9.5M, up 12% Y/Y, and consisted solely of net product revenue. Cost of sales was $6M, +20% over the prior-year period. Gross margin soared to 37% compared to 9% in Q411, driven largely by an increase in average net selling prices. Comment! [Healthcare, Earnings, On the Move]
-
Friday, March 15, 9:15 AM
Premarket gainers: CNP +10%. SNE +8%. ZGNX +6%. OGE +6%. PANL +5%.
Losers: GLDD -22%. ULTA -14%. STEC -13%. ARO -7%. VHC -6%. CG -6%. KKD -5%. Comment! [On the Move] - Friday, March 15, 7:39 AM Zogenix (ZGNX): Q4 EPS of -$0.16 beats by $0.01. Revenue of $9.5M misses by $0.37M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Friday, March 15, 12:05 AM Notable earnings before Friday’s open: CRME, PGNX, ZGNX Comment! [Earnings]
- Thursday, March 14, 5:30 PM Notable earnings before Friday’s open: CRME, PGNX, ZGNX Comment! [Earnings]
-
Thursday, February 28, 12:53 PM
Midday top 10 gainers: RNIN +65%. IFMI +60%. HGSH +23%. ANIK +18%. FSGI +17%. PANL +16%. LTBR +16%. ZGNX +15%. FARO +14%. ATSG +13%.
Midday top 10 losers: PKT -29%. BSFT -28%. IMH -20%. GRPN -19%. JCP -15%. FREE -12%. AMBO -12%. GVA -11%. TEO -11%. DVR -11%. Comment! [On the Move] -
Thursday, February 28, 9:10 AM
Premarket gainers: MNOV +11%. BDBD +10%. RTK +8%. ZGNX +7%. NEO +7%. NBG +6%.
Losers: GRPN -29%. BSFT -23%. JCP -16%. PKT -15%. MTG -14%. MCP -8%. CWH -7%. 1 Comment [On the Move] -
Wednesday, February 27, 12:55 PM
Midday top 10 gainers: ZGNX +39%. UNXL +24%. FSGI +21%. GWRE +18%. ELMD +16%. PDCE +14%. OPTR +13%. DLTR +12%. END +11%. SHI +11%.
Midday top 10 losers: AH -26%. CBB -23%. AMBO -22%. RNIN -21%. CBMX -19%. XWES -19%. FSLR -16%. CMGE -15%. CRMB -13%. PRPH -12%. Comment! [On the Move] - Wednesday, February 27, 10:49 AM Zogenix (ZGNX +44%) continues to surge higher this morning on the news of the FDA decision to push back its PDUFA date for Zohydro. Analysts see the delay as a potential positive, as it's likely to be short-lived and the odds for eventual approval are still high. Wells Fargo's Michael Tong sees just 20% downside on a negative FDA decision but potentially 100%+ upside for the stock if given the green light. Comment! [Healthcare, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Scott Matusow
From yesterday: $ZGNX chart and $SRPT: Did I get it right? find out at http://bit.ly/Qss4GL - View all 8 replies
-
Scott Matusow: Thanks Guys! and good to hear Droney, glad I can help offer ideas to people. Thank Seeking Alpha as well for allowing so many diverse ideas.
-
-
- View all 2 replies
-
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 11 replies
-
DAG1996: yes. i factor some losses into my biotech plays... as long as i make more than i lose i'm happy. lol
-
LATEST REPLIES
-
Scott Matusow
From yesterday: $ZGNX chart and $SRPT: Did I get it right? find out at http://bit.ly/Qss4GL - View all 8 replies
-
Scott Matusow: Thanks Guys! and good to hear Droney, glad I can help offer ideas to people. Thank Seeking Alpha as well for allowing so many diverse ideas.
-
-
- View all 2 replies
-
-
-
- View all 11 replies
-
DAG1996: yes. i factor some losses into my biotech plays... as long as i make more than i lose i'm happy. lol
-
-
Husky Financial
CRR and KIT two of my stock screen highlights from tonight. Also added TRU and ZGNX to the watch list as well.I wrote an entire blog on this - View all 9 replies
-
Husky Financial: 164m mkt cap 70m in cash on the books..87% inst. owned.. dunno on an entry.. maybe $2.00-$2.25? got some nice stuff in the pipeline
-
DAG1996: ok i misunderstood. yes, good inst. onws & decent cash. bios burn cash very fast though. some political issues too. i'll probably open small